About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:5806781
Allelic
Composition
Gt(ROSA)26Sortm4(CAG-hsb5)Nki/Gt(ROSA)26Sor+
Tg(Mx1-cre)1Cgn/0
Tg(Tal1-tTA)19Dgt/0
Tg(tetO-BCR/ABL1)2Dgt/0
TgTn(pb-sb-GrOnc)#aGsva/0
Genetic
Background
involves: 129P2/OlaHsd * C57BL/6 * CBA/J * DBA/2 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm4(CAG-hsb5)Nki mutation (0 available); any Gt(ROSA)26Sor mutation (497 available)
Tg(Mx1-cre)1Cgn mutation (6 available)
Tg(Tal1-tTA)19Dgt mutation (2 available)
Tg(tetO-BCR/ABL1)2Dgt mutation (1 available)
TgTn(pb-sb-GrOnc)#aGsva mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice withdrawn from tetracycline and treated with polyinosine-polycyticylic acid (pIpC) show a decrease in survival with median survival of 116.5 days

neoplasm
• majority of pIpC treated mice (85%) develop an exclusively myeloid and primary acute leukemia phenotype
• 5% of mice remain in the chronic phase of the disease
• about 10% of mice develop an accelerated phase-like phenotype but with less than 20% blasts
• however, mice do not develop lymphoid leukemias

hematopoietic system
• hemoglobin levels are decreased in pIpC treated mice
• upon withdrawal of tetracycline and treatment with pIpC, mice develop moderate, but persistent (2-3 fold) increase of white blood counts
• white blood cell counts at the terminal endpoint are elevated, indicating a dramatic preterminal proliferative change in kinetics of their disease
• upon withdrawal of tetracycline and treatment with pIpC, mice show marked expansion of the granulocyte compartment
• increase in infiltration of tissues with both granulocytes and immature cells
• disease progression in in pIpC treated mice is frequently accompanied by an increase in basophils
• the myeloid progenitor compartment is expanded in pIpC treated mice, including the granulocyte monocyte progenitor compartment
• expansion of the lineage-negative (Lin-) bone marrow fraction in pIpC treated mice
• however, no differences are seen in total Lin-Sca+c-kit+ (LSK) numbers, long-term and short-term hematopoietic stem cell or multipotent progenitor proportions
• in pIpC treated mice
• hematopoietic stem cells show an increased ability to serially replate compared to control cells

immune system
• upon withdrawal of tetracycline and treatment with pIpC, mice develop moderate, but persistent (2-3 fold) increase of white blood counts
• white blood cell counts at the terminal endpoint are elevated, indicating a dramatic preterminal proliferative change in kinetics of their disease
• upon withdrawal of tetracycline and treatment with pIpC, mice show marked expansion of the granulocyte compartment
• increase in infiltration of tissues with both granulocytes and immature cells
• disease progression in in pIpC treated mice is frequently accompanied by an increase in basophils
• in pIpC treated mice

liver/biliary system
• in pIpC treated mice

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
chronic myeloid leukemia DOID:8552 OMIM:608232
J:227558


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
09/10/2019
MGI 6.14
The Jackson Laboratory